The Propaganda for Reform in Proprietary Medicines, Vol. 1 of 2Council on Pharmacy and Chemistry (American Medical Association)
Science
The Propaganda for Reform in Proprietary Medicines, Vol. 1 of 2
Council on Pharmacy and Chemistry (American Medical Association)
Patent medicines
CASE 10.--This was in a child of 8 years which was treated by the
investigator’s confrère and gave similar negative results. Blood
examination showed numerous parasites. The child was placed on 1
ounce of Sinkina three times a day and kept on it for two weeks.
The clinical picture remained unaltered, and parasites could be
detected in numbers whenever examinations were conducted. A gradually
increasing enlargement of the spleen was also noted. At the end of
two weeks quinin was substituted, and the child went on to a rapid
and uneventful recovery.
This investigator also concludes that the claim put forth by the
Metropolitan Pharmacal Company that Sinkina is a specific in the
treatment of the malarial fevers is entirely without foundation, and
that the firm will be unable to demonstrate to the contrary.
These investigations demonstrate that Sinkina is not a specific against
malaria, and that it has no more effect than a mixture of oil of cumin,
sugar, alcohol and water. They further show the fallacy, first, of
concluding from a temporary cessation of the symptoms in malaria that
the disease has been cured and, second, of ascribing such temporary
improvement to the influence of a remedy which has no known effect on
the malarial organism.--(_From the Journal A. M. A., Sept. 27, 1913._)
SOMNOS
Report of the Council on Pharmacy and Chemistry
_To the Council on Pharmacy and Chemistry of the American Medical
Association:_--Your subcommittee, to whom was assigned Somnos,
H. K. Mulford Company, submits the following report of experiments,
undertaken to compare the effects of Somnos with those of chloral
hydrate. These experiments demonstrate that the statements made in
regard to the action of Somnos are in conflict with Rule 6 of the
Council, which requires: “No article will be admitted or retained
concerning which the manufacturer or his agents make unwarranted,
exaggerated or misleading statements as to the therapeutic value.” It
is, therefore, recommended that Somnos be not approved for inclusion
in the book until the claims made for it are corrected. It is also
recommended that the report be published:
The Pharmacology of Somnos
Public-domain text, read in full here on John Shaqi.
Reviews
Reviews
No reviews yet
Be the first to share your thoughts on this work.
Elsewhere in the archive
Join the Discussion
Join the discussion
Sign in to leave a comment or review.
Sign InorCreate an account